MedTrace Logo

Use of Activated Recombinant Human Factor VII in Cardiac Surgery

NCT00154427 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2017-01-12

No results posted yet for this study

Summary

This trial is conducted in Africa, Asia, Europe, South America and the United States of America (USA).

The trial is planned to investigate the safety and efficacy of NovoSeven® in the management of post-operative bleeding in patients following cardiac surgery.

Conditions

  • Acquired Bleeding Disorder
  • Cardiac Surgery Requiring Cardiopulmonary Bypass

Interventions

DRUG

activated recombinant human factor VII

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States
  • Argentina
  • Brazil
  • Denmark
  • France
  • Germany
  • India
  • Italy
  • Malaysia
  • Singapore
  • South Africa
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00154427 on ClinicalTrials.gov